Search results
GSK’s asthma drug shows promise in reducing severe attacks
WHTC 1450 Holland· 6 days ago(Reuters) - GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period...
GSK Experimental Drug Reduces Severe Asthma Attacks in Key Trial
Bloomberg· 6 days agoAn experimental drug from GSK Plc reduced asthma attacks in late-stage trials, paving the way for a...
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Benzinga via Yahoo Finance· 6 days agoTuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and...
Asthma Triggers In Homes Can Send Kids to the ER—This Organization Is Working to Change That
Health.com· 6 days agoFor parents of children with asthma, witnessing an attack of severe symptoms can be a terrifying...
GSK's experimental drug shows promise in reducing severe asthma attacks
Reuters via AOL· 6 days agoThe drug, called depemokimab, showed "significant and meaningful reductions" in asthma attacks for...
Manage Your Asthma: FDA on Know Your Triggers and Treatment Options
Sierra Sun Times· 6 days agoAsthma is a chronic lung disease that causes the airways to become inflamed and narrow. Symptoms of...
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — 2nd Update
Morningstar· 6 days agoThe British pharmaceutical company's depemokimab drug reduced asthma attacks in late-stage trials for patients with severe eosinophilic ...
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Zacks via Yahoo Finance· 5 days agoGSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma...
Research finds few moderate or severe asthma patients prescribed recommended inhaler regimen
Medical Xpress· 6 days agoIn the United States, ICS-formoterol inhalers include Symbicort (budesonide-formoterol) and Dulera...
Potential blockbuster asthma drug met goals in trials, GSK says
Morningstar· 6 days agoGSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than GBP3 billion ($3.8 billion) met their goals. GSK (GSK) (UK:GSK) said both ...